DNA biomarker tests Multiple Myeloma
A company located in Buffalo's Medical Corridor has unveiled the first DNA biomarker test to be used to treat a certain type of blood cancer.
The test from Empire Genomics is for Multiple Myeloma. The malignant blood cell cancer can provide many challenges for physicians trying to treat individuals the condition.
But Empire Genomics says this new DNA test will allow doctors to tailor treatment for patients based on their genetic makeup. Company CEO Anthony Johnson said the test will help physicians improve treatment for patients.
"Treatment and therapy for these patients that suffer with Multiple Myeloma by not giving them drugs that we know will not work for them, and in fact have other side effects," said Johnson.
Dr. Norma Nowak, company found and chief scientific officer, said the test will allow doctors to tailor treatment for patients based on their genetic makeup.
"What you end up doing is treat the patients who will benefit from the current first line treatment, then you are able to prevent the other patients the drug won't do any good, so you don't administer that drug, they don't suffer the side effects. Instead you put them on a path for an alternative treatment," said Dr. Nowak.
The company is also launching a clinical lab. This is expected to lead to the creation of more than 50 new jobs with the next five years. Empire Genomics is located on Michigan Avenue.